Baird lowered the firm’s price target on Syndax to $28 from $32 and keeps an Outperform rating on the shares. The firm believes its topline data is more likely than not good enough to support approval in the U.S. and also supports that the NPM1 pivotal cohort still underway could be successful as well. Baird believes the selloff in the shares is overdone as well.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SNDX:
- Syndax price target raised to $42 from $38 at H.C. Wainwright
- Syndax announces ‘positive’ results from AUGMENT-101 trial of revumenib
- Syndax put volume heavy and directionally bearish
- Syndax call volume above normal and directionally bullish
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)